Literature DB >> 7731917

Etiology of ovarian dysfunction in chronic murine toxoplasmosis.

W Stahl1, J A Dias, G Turek, Y Kaneda.   

Abstract

Ovarian dysfunction develops in Nya:NYLAR mice chronically infected with Toxoplasma gondii. To differentiate between primary ovarian failure and pituitary gonadotropin insufficiency, we (a) monitored ovarian responsiveness to pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) and (b) assessed endogenous pituitary gonadotropin capacity by the degree of ovarian compensatory hypertrophy (OCH) developing after unilateral ovariectomy (ULO). PMSG stimulated vigorous folliculogenesis and estrogen synthesis, but not ovulation. HCG given 3 days after PMSG induced "superovulation" within 16 h. These observations indicate the absence of the critical preovulatory surge of endogenous luteinizing hormone (LH) from the pituitary. In addition, ULO did not result in compensatory hypertrophy of the contralateral ovary, an indication of follicle-stimulating hormone (FSH) insufficiency. We hypothesize that cytokines released peripherally in response to the parasite reached the hypothalamus and initiated a sequence of events that inhibited the pulsatile release of gonadotropin-releasing hormone (GnRH), leading to the subsequent impairment of the pituitary-ovarian axis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731917     DOI: 10.1007/bf00931615

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  36 in total

Review 1.  Pathophysiological aspects of acute experimental allergic encephalomyelitis.

Authors:  M Juhler
Journal:  Acta Neurol Scand Suppl       Date:  1988

2.  Involvement of brain catecholamines in the gonadotropins-releasing mechanism(s) before puberty.

Authors:  E E Müller; D Cocchi; A Villa; F Zambotti; F Fraschini
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

3.  Increase in serum FSH following unilateral ovariectomy in the rat.

Authors:  B Benson; S Sorrentino; J S Evans
Journal:  Endocrinology       Date:  1969-02       Impact factor: 4.736

4.  Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation.

Authors:  F Petraglia; S Sutton; W Vale; P Plotsky
Journal:  Endocrinology       Date:  1987-03       Impact factor: 4.736

Review 5.  Microglial secretion products and their impact on the nervous system.

Authors:  D Giulian; M Corpuz
Journal:  Adv Neurol       Date:  1993

6.  Changes in the effectiveness of the blood-brain and blood-spinal cord barriers in experimental allergic encephalomyelitis.

Authors:  P M Daniel; D K Lam; O E Pratt
Journal:  J Neurol Sci       Date:  1981 Nov-Dec       Impact factor: 3.181

7.  Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats.

Authors:  P S Kalra; A Sahu; S P Kalra
Journal:  Endocrinology       Date:  1990-04       Impact factor: 4.736

8.  Reproductive failure in mice chronically infected with Toxoplasma gondii.

Authors:  W Stahl; Y Kaneda; T Noguchi
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Uterine atrophy in chronic murine toxoplasmosis due to ovarian dysfunction.

Authors:  W Stahl; Y Kaneda; M Tanabe; S A Kumar
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

10.  In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion.

Authors:  C Rivier; W Vale
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

View more
  2 in total

Review 1.  Human parasitic protozoan infection to infertility: a systematic review.

Authors:  Malihe Nourollahpour Shiadeh; Maryam Niyyati; Shirzad Fallahi; Ali Rostami
Journal:  Parasitol Res       Date:  2015-11-16       Impact factor: 2.289

2.  Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries.

Authors:  Jaroslav Flegr; Joseph Prandota; Michaela Sovičková; Zafar H Israili
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.